Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Key Points
The sale had an approximate value of nearly $350,000.
The transaction reduced the executive's direct equity position by 11%.
Despite the massive gains from the stock over the last 12 months, analysts still remain bullish on Relay.
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (NASDAQ:RLAY), sold 17,717 shares of common stock on Aug. 14, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $349,734 |
| Shares sold | 17,717 |
| Post-transaction shares (directly held) | 140,568 |
| Post-transaction value | $2.8 million |
Transaction value based on SEC Form 4 weighted average sale price ($19.74); post-transaction value based on Aug. 14, 2026, market close ($19.86).
Key questions
- How does this disposal relate to the CFO's overall equity strategy?
The sale was conducted through a pre-arranged Rule 10b5-1 trading plan adopted in October 2025, providing structured liquidity insulated from the timing of specific corporate developments. - What is the current market valuation of the remaining executive stake?
Based on the Aug. 17, 2026, market close of $20.67, the CFO's remaining direct holdings of 140,568 shares have a market value of approximately $2.9 million. - What is the scale of the insider's remaining participation in the company?
Following this 11% reduction in direct holdings, Catinazzo retains a direct equity stake in the firm, which currently has an aggregate insider ownership level of 0.06%. - What financial and performance context surrounded the transaction?
While Relay Therapeutics achieved a 486% return in the year ending Aug. 14, 2026, the company reported a trailing-twelve-month net loss of $286 million on revenue of $10.3 million.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-17) | $20.67 |
| Market Capitalization | $4 billion |
| Revenue (TTM) | $10.3 million |
| Net Income (TTM) | -$286 million |
Company Snapshot
- Relay Therapeutics is a precision medicine company developing small-molecule therapeutic candidates targeting fibroblast growth factor receptors (FGFRs) and other oncology-related pathways, with its lead program, RLY-4008, an orally administered FGFR2 inhibitor currently in clinical trials.
- The company operates a clinical-stage drug development business model, generating minimal revenue from research activities while incurring substantial operating expenses associated with preclinical research, clinical trial execution, and regulatory compliance.
- Relay Therapeutics targets oncology and genetic disease indications, with its primary customer base consisting of institutional investors, research collaborators, and ultimately patients with specific cancer types and genetic conditions once therapies achieve regulatory approval.
Relay Therapeutics is a clinical-stage precision medicine company with a market capitalization of $4 billion, headquartered in Cambridge and employing more than 200 people. The company has demonstrated significant momentum, with shares appreciating 485% over the past year around the time of the transaction, reflecting investor confidence in its drug development pipeline. As a pre-revenue stage biotechnology enterprise, Relay's competitive positioning depends on the clinical efficacy and regulatory pathway of its small molecule candidates, particularly RLY-4008, which addresses underserved oncology indications with differentiated mechanisms of action.
What this transaction means for investors
Given how high the stock price has climbed over the past 12 months, this trade being pre-established, and the number of shares the executive still retains, this appears to be largely a routine sale. While Catinazzo sold 17,717 shares, he still holds direct ownership of 140,568 shares, indicating continued alignment with Relay's success. And given that, as of this writing, the stock price has climbed over 400% in the past 12 months, this transaction doesn't seem to indicate any issues with the company that fueled the sale.
Given that the stock price has climbed so much over the last year, analysts still expect plenty of gains over the next 12 months, albeit not as much as in the past year. According to CNN, 100% of the 14 analysts who cover the stock rate it as a buy. The median one-year price target from that group is $26, representing a 40.9% potential gain from the stock price as of this writing. The highest price target is $31, representing a potential gain of 68%, while the lowest price target is $20, which still represents a potential gain of 8.4%. Any positive updates to the drug pipeline could help fuel continued significant returns, while any setbacks could trigger a sharp price pullback.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.